The realization that defined tumor antigens can serve as targets for recognition by T lymphocytes has motivated attempts at developing and optimizing immunologic therapies for the treatment of cancer. This excitement has been reinforced by the success of two humanized monoclonal antibodies, Herceptin and Rituxan, for the treatment of breast cancer and lymphoma, respectively, as well as the approval of two cytokines, interleukin-2 and interferon-alpha, for the treatment of melanoma. The development of new immune-based therapies, such as cancer vaccines and novel cytokines, and the elucidation of the mechanism of action of currently available treatments, require careful monitoring of scientific endpoints to determine the optimal biologically active dose and schedule of these agents. The purpose of the Human Immunologic Monitoring Facility is to perform such assays in the context of clinical trials in cancer patients. This service enables a range of clinical cancer researchers, who may not themselves have the expertise or laboratory commitment to carry out these assays, to measure Immunotherapy Group as it develops cancer treatment strategies involving vaccines, monoclonal antibodies, cytokines, and cell-based therapies. immunologic endpoints in participating study subjects. Assays currently performed include measurement of T cell cytokine production, proliferation, and cytolytic activity; serum cytokine content; flow cytometric analysis of hematopoietic and T cell subsets; induced intracellular cytokines by flow cytometry; and RT-PCR analysis of tumor antigen gene expression. Preparation of peptide-based cancer vaccines is also performed. New assays are under development that will incorporate the latest techniques and enable important new scientific questions to be asked in the clinical setting. In sum, this facility provides clinical trial laboratory support for our Cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-28
Application #
6599158
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-15
Project End
2007-03-31
Budget Start
Budget End
Support Year
28
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5

Showing the most recent 10 out of 668 publications